The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target?

Glioblastoma IDH-wildtype represents the most lethal and frequent primary tumor of the central nervous system. Thanks to important scientific efforts, we can now investigate its deep genomic assessment, elucidating mutated genes and altered biological mechanisms in addition to its clinical aggressiveness. The telomerase reverse transcriptase gene (TERT) is the most frequently altered gene in solid tumors, including brain tumors and GBM IDH-wildtype. In particular, it can be observed in approximately 80–90% of GBM IDH-wildtype cases. Its clonal distribution on almost all cancer cells makes this gene an optimal target. However, the research of effective TERT inhibitors is complicated by several biological and clinical obstacles which can be only partially surmounted. Very recently, novel immunological approaches leading to TERT inhibition have been investigated, offering the potential to develop an effective target for this altered protein. Here, we perform a narrative review investigating the biological role of TERT alterations on glioblastoma and the principal obstacles associated with TERT inhibitions in this population. Moreover, we discuss possible combination treatment strategies to overcome these limitations.

[1]  A. von Deimling,et al.  A Novel Type of IDH-wildtype Glioma Characterized by Gliomatosis Cerebri-like Growth Pattern, TERT Promoter Mutation, and Distinct Epigenetic Profile , 2023, The American journal of surgical pathology.

[2]  E. Franceschi,et al.  DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open , 2023, Cancers.

[3]  Yunhui Li,et al.  Zeolitic Imidazolate Framework-8 (ZIF-8) as a Drug Delivery Vehicle for the Transport and Release of Telomerase Inhibitor BIBR 1532 , 2023, Nanomaterials.

[4]  V. Zagonel,et al.  Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients , 2023, ESMO open.

[5]  J. Shay,et al.  Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma , 2023, Molecular cancer therapeutics.

[6]  A. Olivi,et al.  Telomerase inhibition in malignant gliomas: a systematic review , 2023, Expert Reviews in Molecular Medicine.

[7]  E. Franceschi,et al.  Tumor Microenvironment in Gliomas: A Treatment Hurdle or an Opportunity to Grab? , 2023, Cancers.

[8]  John G Doench,et al.  Telomerase inhibition is an effective therapeutic strategy in TERT promoter mutant-glioblastoma models with low tumor volume. , 2023, Neuro-oncology.

[9]  Susan M. Chang,et al.  GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer , 2022, Cell reports.

[10]  A. Brandes,et al.  Tumor-Associated Microenvironment of Adult Gliomas: A Review , 2022, Frontiers in Oncology.

[11]  F. Lieberman,et al.  Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma. , 2022, Journal of Clinical Oncology.

[12]  Z. Zhou,et al.  Structure of active human telomerase with telomere shelterin protein TPP1 , 2022, Nature.

[13]  A. Brandes,et al.  Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date? , 2022, Drugs.

[14]  T. Maehara,et al.  TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma , 2021, Acta Neuropathologica.

[15]  F. Giangaspero,et al.  TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH-wildtype glioblastoma? , 2021, Neuro-oncology.

[16]  T. Cech,et al.  Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization , 2021, Nature Reviews Molecular Cell Biology.

[17]  G. Reifenberger,et al.  EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood , 2020, Nature Reviews Clinical Oncology.

[18]  K. Hoang-Xuan,et al.  IDH-wildtype lower grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. , 2020, Neuro-oncology.

[19]  J. Villanueva,et al.  TARGETING TELOMERASE FOR CANCER THERAPY , 2020, Oncogene.

[20]  I. Dunn,et al.  The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis , 2020, BMC Cancer.

[21]  J. Doudna,et al.  Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage , 2020, Proceedings of the National Academy of Sciences.

[22]  R. DePinho,et al.  Programmable base editing of mutated TERT promoter inhibits brain tumour growth , 2020, Nature Cell Biology.

[23]  G. Reifenberger,et al.  cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas , 2020, Acta Neuropathologica.

[24]  T. Shofuda,et al.  TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma , 2020, Neuro-oncology advances.

[25]  M. J. van den Bent,et al.  EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. , 2019, The Lancet. Oncology.

[26]  M. Mafra,et al.  Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation , 2019, BMC Cancer.

[27]  Gabriele Schackert,et al.  Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. , 2019, Cancer cell.

[28]  Jun S. Song,et al.  Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner. , 2018, Cancer cell.

[29]  Qiong Wang,et al.  The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI‐derived and clinical features, predict adult primary glioblastoma survival , 2018, Cancer medicine.

[30]  R. McLendon,et al.  The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma , 2018, Nature Communications.

[31]  Gad Getz,et al.  Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens , 2017, npj Precision Oncology.

[32]  Jennie W. Taylor,et al.  Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT , 2017, Acta Neuropathologica.

[33]  M. Zanetti.  A second chance for telomerase reverse transcriptase in anticancer immunotherapy , 2017, Nature Reviews Clinical Oncology.

[34]  Xin Hu,et al.  Systematic analysis of telomere length and somatic alterations in 31 cancer types , 2017, Nature Genetics.

[35]  W. Chng,et al.  Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas , 2016, Proceedings of the National Academy of Sciences.

[36]  R. Elashoff,et al.  Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy , 2016, Neuro-oncology.

[37]  E. Miyaoka,et al.  A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas , 2016, Acta neuropathologica communications.

[38]  I. Pollack,et al.  A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study , 2016, Journal of Neuro-Oncology.

[39]  Gang Zhao,et al.  Telomere targeting with a novel G-quadruplex-interactive ligand BRACO-19 induces T-loop disassembly and telomerase displacement in human glioblastoma cells , 2016, Oncotarget.

[40]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[41]  B. Vogelstein,et al.  Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers , 2015, Genes & development.

[42]  S. Spiegl-Kreinecker,et al.  Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. , 2015, Neuro-oncology.

[43]  M. Stenmark-Askmalm,et al.  TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma , 2015, Oncotarget.

[44]  Chibo Hong,et al.  The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer , 2015, Science.

[45]  T. Kolevska,et al.  A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  Guido Sauter,et al.  Frequency of TERT promoter mutations in primary tumors of the liver , 2014, Virchows Archiv.

[47]  Y. Marie,et al.  Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes , 2014, Neurology.

[48]  Yilin Yang,et al.  Association between telomerase reverse transcriptase rs2736100 polymorphism and risk of glioma. , 2014, The Journal of surgical research.

[49]  K. Kinzler,et al.  TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. , 2013, Cancer research.

[50]  David T. W. Jones,et al.  Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system , 2013, Acta Neuropathologica.

[51]  P. Kleihues,et al.  TERT promoter mutations in primary and secondary glioblastomas , 2013, Acta Neuropathologica.

[52]  S. Aamdal,et al.  Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma , 2013, Cancer Immunology, Immunotherapy.

[53]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[54]  Lynda Chin,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.

[55]  J. Shay,et al.  Early and late steps in telomere overhang processing in normal human cells: the position of the final RNA primer drives telomere shortening. , 2012, Genes & development.

[56]  E. Maher,et al.  The Telomerase Antagonist, Imetelstat, Efficiently Targets Glioblastoma Tumor-Initiating Cells Leading to Decreased Proliferation and Tumor Growth , 2010, Clinical Cancer Research.

[57]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[58]  P. Klatt,et al.  Expression of mTert in primary murine cells links the growth-promoting effects of telomerase to transforming growth factor-β signaling , 2006, Oncogene.

[59]  D. Trisciuoglio,et al.  Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function , 2005, Cell Death and Differentiation.

[60]  W. Hahn,et al.  The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[61]  W. Hahn,et al.  Telomerase and tumorigenesis. , 2003, Cancer letters.

[62]  M. Meyerson,et al.  Role of telomerase in normal and cancer cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  W. Hahn,et al.  Inhibition of telomerase limits the growth of human cancer cells , 1999, Nature Medicine.

[64]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[65]  J. Schramm,et al.  TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. , 2015, Neuro-oncology.

[66]  J. Higginson.  International Agency for Research on Cancer. , 1968, WHO chronicle.